Healthcare Losers: Exelixis (NASDAQ:EXEL), CytRx Corporation (NASDAQ:CYTR), Array Biopharma (NASDAQ:ARRY), Acorda Therapeutics (NASDAQ:ACOR)

Shares of Exelixis Inc (NASDAQ:EXEL) were down 8.5% during trading on Friday after the company announced weaker than expected quarterly earnings. Exelixis, Inc. (NASDAQ:EXEL) stock opened at $3.50 in last session, and closed at $3.32, while the day range of EXEL stock is $3.21 – $3.51. The stock showed a positive weekly performance of 1.84%.

CytRx Corporation (NASDAQ:CYTR) posted its quarterly earnings results on Thursday. The company reported $0.09 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.18) by $0.27. A number of analysts have recently weighed in on CYTR shares. Analysts at Aegis reiterated a “buy” rating on shares of CytRx Corporation (NASDAQ:CYTR) in a research note on Monday, March 17th. CytRx Corporation as (NASDAQ:CYTR) is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, specializing in oncology. CytRx Corporation (NASDAQ:CYTR) stock opened at $3.58, in last session and closed at $3.22, by losing -9.30%. The 52 week range of is $1.95 – $8.35. Company’s market capitalization is $178.92million.

Array Biopharma Inc (NASDAQ:ARRY) gained 7.54% after the company reported third quarter earnings results. Array Biopharma Inc (NASDAQ:ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array Biopharma Inc (NASDAQ:ARRY) stock decreased -5.61% and finished the last session at $4.04. The EPS of the stock remained -0.62. Company’s market capitalization is $506.84million.

Acorda Therapeutics Inc (NASDAQ:ACOR) said the U.S. Food and Drug Administration rejected its nasal form of the current standard therapy for epilepsy patients who experience repetitive seizures. The biotechnology company’s shares fell as much as 11 percent after it said that it does not expect the treatment to receive regulatory approval this year. Acorda Therapeutics Inc (NASDAQ:ACOR) stock opened the session at $34.50, and closed the session at $32.39. The 52 week range of the stock remained $27.51 – $39.94 and the day range was $31.95 – $34.60.